RINKEL MOLD MIX B is a Percutaneous; Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Allergy Laboratories, Inc.. The primary component is Trichothecium Roseum; Passalora Fulva; Cochliobolus Spicifer; Myrothecium Verrucaria; Trichophyton Schoenleinii; Mycogone Nigra; Neurospora Crassa; Khuskia Oryzae; Paecilomyces Variotii; Microascus Brevicaulis; Helminthosporium Solani; Pleospora Tarda; Streptomyces Griseus; Trichoderma Viride.
| Product ID | 54575-229_dbe7bebd-e445-4e59-8302-e706b795fbde |
| NDC | 54575-229 |
| Product Type | Human Prescription Drug |
| Proprietary Name | RINKEL MOLD MIX B |
| Generic Name | Trichothecium Roseum And Passalora Fulva And Cochliobolus Spicifer And Myrothecium Verrucaria And Trichophyton Schoenleinii And Mycogone Nigra And Neurospora Crassa And Khuskia Oryzae And Paecilomyces |
| Dosage Form | Injection, Solution |
| Route of Administration | PERCUTANEOUS; SUBCUTANEOUS |
| Marketing Start Date | 1967-12-07 |
| Marketing Category | BLA / BLA |
| Application Number | BLA101376 |
| Labeler Name | Allergy Laboratories, Inc. |
| Substance Name | TRICHOTHECIUM ROSEUM; PASSALORA FULVA; COCHLIOBOLUS SPICIFER; MYROTHECIUM VERRUCARIA; TRICHOPHYTON SCHOENLEINII; MYCOGONE NIGRA; NEUROSPORA CRASSA; KHUSKIA ORYZAE; PAECILOMYCES VARIOTII; MICROASCUS BREVICAULIS; HELMINTHOSPORIUM SOLANI; PLEOSPORA TARDA; STREPTOMYCES GRISEUS; TRICHODERMA VIRIDE |
| Active Ingredient Strength | 0 g/20mL; g/20mL; g/20mL; g/20mL; g/20mL; g/20mL; g/20mL; g/20mL; g/20mL; g/20mL; g/20mL; g/20mL; g/20mL; g/20mL |
| Pharm Classes | Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [CS],Allergens [CS],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [CS],Allergens [CS],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [CS],Allergens [CS],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [CS],Allergens [CS],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [CS],Allergens [CS],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [CS],Allergens [CS],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [CS],Allergens [CS],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [CS],Allergens [CS],Allergens [CS],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [CS],Increased IgG Production [PE],Fungal Proteins [CS],Allergens [CS],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Non-Standardized Bacterial Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Bacterial Proteins [CS],Allergens [CS],Fungal Proteins [CS],Allergens [CS],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE] |
| NDC Exclude Flag | E |
| Listing Certified Through | 2018-12-31 |
| Marketing Start Date | 1967-12-07 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | BLA |
| Application Number | BLA101376 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 1967-12-07 |
| Inactivation Date | 2020-01-31 |
| Marketing Category | BLA |
| Application Number | BLA101376 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 1967-12-07 |
| Inactivation Date | 2020-01-31 |
| Marketing Category | BLA |
| Application Number | BLA101376 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 1967-12-07 |
| Inactivation Date | 2020-01-31 |
| Marketing Category | BLA |
| Application Number | BLA101376 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 1967-12-07 |
| Inactivation Date | 2020-01-31 |
| Ingredient | Strength |
|---|---|
| TRICHOTHECIUM ROSEUM | .071 g/20mL |